Vir Biotechnology (VIR) News Today $6.95 -0.25 (-3.47%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$7.04 +0.09 (+1.22%) As of 08:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Vir Biotechnology, Inc. (NASDAQ:VIR) Holdings Raised by Charles Schwab Investment Management Inc.Charles Schwab Investment Management Inc. grew its position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 10.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,252,655 shares of the company's stock after acquiriMarch 23 at 3:09 AM | marketbeat.comBrii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial ResultsMarch 21, 2025 | prnewswire.com51,967 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Bought by Tejara Capital LtdTejara Capital Ltd bought a new position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 51,967 shares of the company's stock, valued at approximately $3March 19, 2025 | marketbeat.comBank of New York Mellon Corp Lowers Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)Bank of New York Mellon Corp reduced its position in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 6.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 604,067 shares of the company's stock after sellingMarch 19, 2025 | marketbeat.comVir enrols first subject in Phase III programme to assess CHD therapyMarch 14, 2025 | finance.yahoo.comVir Biotechnology enrolls first patient in ECLIPSE programMarch 13, 2025 | markets.businessinsider.comVir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by New York State Common Retirement FundNew York State Common Retirement Fund raised its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 163.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 64,90March 5, 2025 | marketbeat.comHepatitis D Market to Expand Significantly by 2034, States DelveInsight Report | Gilead Sciences, Eiger BioPharma, Janssen R&DMarch 4, 2025 | theglobeandmail.comVir Biotechnology: Catalysts Ahead In Hepatitis And OncologyMarch 4, 2025 | seekingalpha.comVir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) have earned a consensus rating of "Moderate Buy" from the six ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and five have assigned aMarch 4, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Shares Gap Down - Time to Sell?Vir Biotechnology (NASDAQ:VIR) Shares Gap Down - Here's What HappenedMarch 3, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for VIR Q1 Earnings?Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Vir Biotechnology in a report issued on Friday, February 28th. HC Wainwright analyst P. Trucchio expects that the company will post earnings of ($0.80) per share for theMarch 3, 2025 | marketbeat.com489,485 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Acquired by Alta Partners Management Company L.P.Alta Partners Management Company L.P. purchased a new position in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 489,485 shares of the company's stock, valued atMarch 2, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Price Target Raised to $31.00 at BarclaysBarclays upped their target price on shares of Vir Biotechnology from $26.00 to $31.00 and gave the company an "overweight" rating in a report on Friday.March 1, 2025 | marketbeat.comVir Biotechnology's (VIR) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $110.00 price target on shares of Vir Biotechnology in a report on Friday.March 1, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Trading Down 8.4% on Insider SellingVir Biotechnology (NASDAQ:VIR) Shares Down 8.4% on Insider SellingFebruary 28, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) EVP Sells $67,389.22 in StockVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) EVP Verneuil Vanina De sold 7,373 shares of the business's stock in a transaction that occurred on Wednesday, February 26th. The stock was sold at an average price of $9.14, for a total value of $67,389.22. Following the transaction, the executive vice president now owns 79,460 shares of the company's stock, valued at approximately $726,264.40. This represents a 8.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.February 28, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Earns Buy Rating from Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $19.00 target price on shares of Vir Biotechnology in a research note on Thursday.February 28, 2025 | marketbeat.comBarclays Remains a Buy on Vir Biotechnology (VIR)February 28, 2025 | markets.businessinsider.comVir Biotechnology price target raised to $31 from $26 at BarclaysFebruary 28, 2025 | markets.businessinsider.comQ4 2024 Vir Biotechnology Inc Earnings CallFebruary 27, 2025 | finance.yahoo.comVir Biotechnology, Inc. (NASDAQ:VIR) Q4 2024 Earnings Call TranscriptFebruary 27, 2025 | msn.comVir Biotechnology (NASDAQ:VIR) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPSVir Biotechnology (NASDAQ:VIR - Get Free Report) posted its earnings results on Wednesday. The company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.09. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%.February 27, 2025 | marketbeat.comVir Biotechnology, Inc. (VIR) Q4 2024 Earnings Call TranscriptFebruary 26, 2025 | seekingalpha.comVir Biotechnology Reports 2024 Financial Results and Strategic AdvancesFebruary 26, 2025 | tipranks.comVir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 26, 2025 | businesswire.comVir Biotechnology director George Scangos sells $107,575 in stockFebruary 22, 2025 | investing.comGeorge A. Scangos Sells 10,964 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR) StockVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) Director George A. Scangos sold 10,964 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $9.81, for a total value of $107,556.84. Following the sale, the director now owns 708,295 shares in the company, valued at approximately $6,948,373.95. This trade represents a 1.52 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.February 20, 2025 | marketbeat.comVir Biotechnology (VIR) to Release Earnings on ThursdayVir Biotechnology (NASDAQ:VIR) will be releasing earnings after the market closes on Thursday, February 27. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=665614)February 20, 2025 | marketbeat.comVir Biotechnology to Participate in TD Cowen 45th Annual Health Care ConferenceFebruary 19, 2025 | businesswire.comVir Biotechnology, Inc. (NASDAQ:VIR) CAO Brent Sabatini Sells 1,562 SharesVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) CAO Brent Sabatini sold 1,562 shares of the stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $9.15, for a total transaction of $14,292.30. Following the sale, the chief accounting officer now directly owns 28,189 shares in the company, valued at $257,929.35. This trade represents a 5.25 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.February 15, 2025 | marketbeat.comInsider Selling: Vir Biotechnology, Inc. (NASDAQ:VIR) CAO Sells 1,562 Shares of StockFebruary 15, 2025 | insidertrades.comEmpowered Funds LLC Lowers Position in Vir Biotechnology, Inc. (NASDAQ:VIR)Empowered Funds LLC cut its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 11.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 290,626 shares of the company's stock after selling 39,February 15, 2025 | marketbeat.comVir Biotechnology SVP sells shares for $14,291February 14, 2025 | msn.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Irhythm Technologies (IRTC), Vir Biotechnology (VIR) and Biogen (BIIB)February 13, 2025 | markets.businessinsider.comState of Alaska Department of Revenue Increases Stock Holdings in Vir Biotechnology, Inc. (NASDAQ:VIR)State of Alaska Department of Revenue increased its holdings in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 33.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 202,441 shares ofFebruary 13, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Shares Down 4.8% - Time to Sell?Vir Biotechnology (NASDAQ:VIR) Stock Price Down 4.8% - Here's What HappenedFebruary 10, 2025 | marketbeat.comabrdn plc Invests $2.67 Million in Vir Biotechnology, Inc. (NASDAQ:VIR)abrdn plc purchased a new stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 363,161 shares of the company's stock, valued at approximately $2,666,000.February 10, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the six analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have given a buy recommendatioFebruary 7, 2025 | marketbeat.comWhat is HC Wainwright's Forecast for VIR FY2029 Earnings?Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Stock analysts at HC Wainwright reduced their FY2029 earnings per share estimates for shares of Vir Biotechnology in a research report issued on Friday, January 31st. HC Wainwright analyst P. Trucchio now forecasts that the company will earn $2February 3, 2025 | marketbeat.comVir Biotechnology, Inc. (NASDAQ:VIR) Sees Significant Increase in Short InterestVir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) was the target of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 7,860,000 shares, a growth of 20.0% from the December 31st total of 6,550,000 shares. Based on an average daily volume of 2,140,000 shares, the short-interest ratio is currently 3.7 days. Currently, 9.0% of the company's shares are sold short.February 1, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR)HC Wainwright reissued a "buy" rating and issued a $110.00 price target on shares of Vir Biotechnology in a research report on Friday.January 31, 2025 | marketbeat.comVir Biotechnology appoints new Chief Technical OfficerJanuary 31, 2025 | msn.comVir Biotechnology (NASDAQ:VIR) Shares Down 3.8% - Time to Sell?Vir Biotechnology (NASDAQ:VIR) Stock Price Down 3.8% - Should You Sell?January 24, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Shares Up 6.3% - What's Next?Vir Biotechnology (NASDAQ:VIR) Trading Up 6.3% - Time to Buy?January 23, 2025 | marketbeat.comVir Biotechnology (NASDAQ:VIR) Trading Down 10.4% - What's Next?Vir Biotechnology (NASDAQ:VIR) Shares Down 10.4% - Should You Sell?January 15, 2025 | marketbeat.comVir Biotechnology Receives Buy Rating: Promising TCE Programs and Strategic Focus Boost Growth OutlookJanuary 15, 2025 | markets.businessinsider.comQ1 Earnings Forecast for VIR Issued By Leerink PartnrsVir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Vir Biotechnology in a research note issued on Sunday, January 12th. Leerink Partnrs analyst R. Ruiz forecasts that the company will post earnings ofJanuary 15, 2025 | marketbeat.comJPMorgan Chase & Co. Has $8.14 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)JPMorgan Chase & Co. cut its stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 13.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,086,327 shares of the company's stock after selling 168,971 sharJanuary 15, 2025 | marketbeat.comResearch Analysts Offer Predictions for VIR Q2 EarningsVir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Investment analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for Vir Biotechnology in a research note issued on Sunday, January 12th. Leerink Partnrs analyst R. Ruiz anticipates that the company will post earnings peJanuary 14, 2025 | marketbeat.com Remove Ads Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address VIR Media Mentions By Week VIR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VIR News Sentiment▼1.380.79▲Average Medical News Sentiment VIR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VIR Articles This Week▼35▲VIR Articles Average Week Remove Ads Get Vir Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ZLAB News RARE News SWTX News AKRO News ALVO News RYTM News MRUS News CRNX News IMVT News VKTX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:VIR) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredHere’s Why Tesla Insiders are Dumping SharesTesla has been on a losing streak ever since Elon Musk first visited the White House in early 2025. Our res...Behind the Markets | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vir Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vir Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VIR Stock Free VIR Stock Alerts